| Literature DB >> 32313369 |
Kris A Murray1, Jesús Olivero2, Benjamin Roche3,4,5, Sonia Tiedt6, Jean-Francois Guégan5.
Abstract
Biogeography is an implicit and fundamental component of almost every dimension of modern biology, from natural selection and speciation to invasive species and biodiversity management. However, biogeography has rarely been integrated into human or veterinary medicine nor routinely leveraged for global health management. Here we review the theory and application of biogeography to the research and management of human infectious diseases, an integration we refer to as 'pathogeography'. Pathogeography represents a promising framework for understanding and decomposing the spatial distributions, diversity patterns and emergence risks of human infectious diseases into interpretable components of dynamic socio-ecological systems. Analytical tools from biogeography are already helping to improve our understanding of individual infectious disease distributions and the processes that shape them in space and time. At higher levels of organization, biogeographical studies of diseases are rarer but increasing, improving our ability to describe and explain patterns that emerge at the level of disease communities (e.g. co-occurrence, diversity patterns, biogeographic regionalisation). Even in a highly globalized world most human infectious diseases remain constrained in their geographic distributions by ecological barriers to the dispersal or establishment of their causal pathogens, reservoir hosts and/or vectors. These same processes underpin the spatial arrangement of other taxa, such as mammalian biodiversity, providing a strong empirical 'prior' with which to assess the potential distributions of infectious diseases when data on their occurrence is unavailable or limited. In the absence of quality data, generalized biogeographic patterns could provide the earliest (and in some cases the only) insights into the potential distributions of many poorly known or emerging, or as-yet-unknown, infectious disease risks. Encouraging more community ecologists and biogeographers to collaborate with health professionals (and vice versa) has the potential to improve our understanding of infectious disease systems and identify novel management strategies to improve local, global and planetary health.Entities:
Keywords: biodiversity; diversity; mapping
Year: 2018 PMID: 32313369 PMCID: PMC7163494 DOI: 10.1111/ecog.03625
Source DB: PubMed Journal: Ecography ISSN: 0906-7590 Impact factor: 5.992
Figure 7Global β‐diversity patterns of zoonotic diseases. (A) Hierarchical cluster analysis (UPGMA method) of a global disease‐by‐country presence–absence matrix represented as a circular dendrogram showing how countries group (regionalization) on the basis of the similarity (as measured by Sørensen β‐diversity) of their zoonotic infectious disease assemblages (following Kreft and Jetz 2010, Murray et al. 2015). Colours represent statistically supported groups (n = 11 groups) of countries that share similar diseases, as derived by evaluating results from the Silhouette, Elbow, CH index and Gap statistic tests; (B) global pathogeographic realms for zoonotic diseases derived from (A) (colours for mapping match country clusters identified in (A)). Legend labels indicate the statistically supported regions (first column) and how these align with ‘classic’ zoogeographic realms (second column) (note although the realm label for Nearctic includes Greenland for illustration purposes, the ‘Islands’ group (dark blue) actually includes a large number of small islands plus a few other countries scattered globally (A) that may cluster on the basis of being a depauperate or data deficient group); (C) the relative explanatory value of a range of social and environmental covariates for explaining these global patterns in disease beta diversity, illustrating that mammalian biodiversity is the best predictor of zoonotic disease diversity at a global scale (as derived from a relative importance analysis following multiple regression on distance matrices controlling for the effects of spatial autocorrelation (following Murray et al. (2015)).
Figure 6Schematic illustrating the latitudinal variation and diversity patterns of human infectious diseases. (A) A global view of Earth showing latitudinal bands; (B) disease richness (grey bars): the total number of different human infectious diseases present per latitudinal unit (e.g. 40–45°) increases towards the tropics (adapted from Guernier et al. (2004)); (C) nestedness: a hierarchical pattern of human pathogen composition with the pathogen species found at higher latitudes (darker bars) constituting nested subsets of those in progressively richer communities at lower latitudes (lighter bars) (adapted from Guernier et al. (2004)); (D) disease range size: narrower distributional ranges occur in the tropics (darker circles) for human pathogens compared to higher latitudes (lighter bars) (adapted from Guernier and Guégan (2009)).
Figure 8Comparing approaches to country‐level Ebola risk assessment for Africa. (A) Co‐occurrence (β‐diversity) analysis of historical zoonotic disease occurrence among countries in which Ebola outbreaks have occurred in humans. ‘Higher risk’ countries are defined as those with more similar zoonotic disease diversity to Ebola‐positive countries (human index cases only) (following Murray et al. 2015). Countries with index cases are shown in Fig. 1 (thick black line). (B) Top 22 ranked countries from (A), for comparison with the 22 ‘at risk’ countries as determined by Pigott et al. (2014) (C). (C) ‘At risk’ countries (n = 22, yellow colour) as determined by high resolution spatial modeling aggregated to country level. The underlying model is based on Ebola outbreaks (index cases) in humans and infection in wildlife and analysis of spatial covariates (data from Pigott et al. 2014) (see Fig. 1 for raw model output and description). Yellow indicates countries that contain some environmentally suitable areas for Ebola. Darker colour indicates countries that do not contain areas predicted to be suitable for Ebola. The overlap in top 22 priority countries between (B) and (C) is ~70%. The approach taken in (A/B) requires no specific information about the target disease and could provide a relevant biogeographic ‘prior’ for planning (e.g. having an emergency response plan in place), reacting to novel appearance of diseases (e.g. for prioritizing surveillance), in data poor settings, and for conservative risk assessment. The approach taken in (C) is more refined and specific but also more data intensive (see Fig. 1 for more detail).